BioCryst to buy Astria Therapeutics for $700m in enterprise value
Upon completion of the transaction, Astria CEO Jill Milne is set to join BioCryst's board.
15 October 2025
Upon completion of the transaction, Astria CEO Jill Milne is set to join BioCryst's board.
The partnership will implement Nabla Bio's Joint Atomic Model in Takeda's early-stage development programmes.
While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.
The FDA¡¯s growing aversion to advisory committees stokes concerns around the transparency and scientific grounding of decisions.
Rinvoq was indicated for adults with active UC or CD who are unresponsive or intolerant to TNF blockers.
The pharma will now offer select branded medications for up to 80% less to cash-paying Americans through the TrumpRx.gov DTC platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.